US · ELAN
Elanco Animal Health Incorporated
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Greenfield, IN 46140
- Website
- elanco.com
Price · as of 2025-12-31
$22.51
Market cap 13.12B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $32.46 | +44.2% |
| Intrinsic Value(DCF) | $10.44 | -53.62% |
| Graham-Dodd Method(GD) | $1.23 | -94.56% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $9.18 | $0.00 | |||
| 2018 | $29.40 | $34.23 | $0.00 | $8.52 | $3.88 |
| 2019 | $25.39 | $33.06 | $0.01 | $7.85 | $1.53 |
| 2020 | $34.27 | $34.51 | $0.57 | $0.00 | $0.00 |
| 2021 | $26.49 | $46.51 | $17.04 | $0.00 | $0.00 |
| 2022 | $9.57 | $28.12 | $0.00 | $1.85 | $0.00 |
| 2023 | $16.45 | $27.46 | $0.00 | $0.00 | $0.00 |
| 2024 | $11.14 | $28.31 | $0.00 | $6.83 | $5.83 |
| 2025 | $26.09 | $32.46 | $0.00 | $1.23 | $0.00 |
AI valuation
Our deep-learning model estimates Elanco Animal Health Incorporated's (ELAN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $32.46
- Current price
- $22.51
- AI upside
- +44.2%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$10.44
-53.62% upside
Graham-Dodd
$1.23
-94.56% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ELAN | Elanco Animal Health Inco… | $22.51 | 13.12B | +44% | -54% | -95% | — | -55.82 | 1.98 | 2.75 | 24.29 | — | -7.90 | 43.48% | 5.34% | -4.92% | -3.67% | 2.52% | -1.79% | 0.61 | 1.15 | 2.17 | 0.93 | 5.14 | -16912.00% | 622.00% | -2792.00% | 2.19% | 0.35 | 2.84% | 0.00% | 0.00% | 2.94% | 65.17 | 57.83 | 3.48 | 1.49 |
| ALGN | Align Technology, Inc. | $190.10 | 13.64B | +1% | -52% | -59% | -74% | 33.42 | 3.39 | 3.40 | 15.94 | 6259.75 | 3.96 | 68.33% | 15.27% | 10.17% | 10.39% | 14.49% | 6.59% | 0.02 | — | 1.36 | 1.14 | -1.27 | 53.00% | 90.00% | -473.00% | 4.33% | 0.31 | 19.89% | 0.00% | 0.00% | 0.64% | 20.61 | 21.41 | 3.15 | 4.87 |
| EHC | Encompass Health Corporat… | $107.88 | 10.85B | -27% | -39% | -66% | -6% | 19.15 | 3.38 | 1.83 | 7.87 | 78.34 | 6.82 | 21.72% | 17.74% | 9.54% | 21.47% | 20.72% | 8.33% | 0.08 | 8.55 | 1.08 | 0.83 | 0.14 | 2444.00% | 1046.00% | 2190.00% | 4.04% | 1.41 | 10.83% | 0.65% | 12.50% | 24.52% | 10.50 | 25.17 | 1.86 | 3.05 |
| ENSG | The Ensign Group, Inc. | $214.17 | 12.45B | -38% | +33% | -70% | -27% | 35.93 | 5.54 | 2.45 | 28.09 | 255.48 | 5.81 | 13.74% | 8.58% | 6.80% | 16.92% | 7.20% | 6.80% | 1.86 | 54.31 | 1.42 | 1.35 | 6.43 | 1406.00% | 1872.00% | 9620.00% | 3.00% | 0.63 | 8.15% | 0.12% | 4.20% | 0.29% | 36.77 | 43.03 | 3.15 | 4.02 |
| NBIX | Neurocrine Biosciences, I… | $132.25 | 13.27B | +32% | +46% | -57% | +4% | 27.52 | 4.05 | 4.60 | 18.16 | 65.61 | 4.05 | 98.18% | 21.64% | 16.73% | 16.38% | 20.21% | 11.46% | 0.13 | — | 3.39 | 2.92 | -0.45 | 4195.00% | 2145.00% | 3437.00% | 5.68% | 1.05 | 36.02% | 0.00% | 0.00% | 5.22% | 19.56 | 16.17 | 4.23 | 7.39 |
| QGEN | Qiagen N.V. | $49.80 | 10.26B | +6% | -52% | -77% | -45% | 23.90 | 2.69 | 4.86 | 14.93 | 5.47 | 14.69 | 61.79% | 24.90% | 20.33% | 11.57% | 10.79% | 7.09% | 0.44 | 15.65 | 3.90 | 2.93 | 1.14 | 43684.00% | 565.00% | -1049.00% | 4.46% | 1.28 | 10.85% | 0.53% | 12.80% | 1.82% | 20.58 | 23.63 | 5.12 | 3.92 |
| RDY | Dr. Reddy's Laboratories … | $14.38 | 11.97B | -27% | +23% | -53% | +28% | 19.94 | 3.42 | 3.51 | 11.69 | 1373.07 | 5.08 | 58.50% | 22.07% | 17.37% | 18.65% | 19.79% | 13.00% | 0.14 | 25.40 | 1.92 | 1.29 | 0.33 | 145.00% | 1661.00% | -3316.00% | 1.05% | 0.36 | 4.44% | 0.58% | 11.60% | 0.71% | 15.73 | 93.95 | 3.47 | 6.72 |
| RVMD | Revolution Medicines, Inc… | $102.02 | 19.72B | — | — | — | — | -17.08 | 11.84 | — | -16.01 | -25.80 | 12.38 | 0.00% | — | — | -58.07% | 1908.09% | -46.06% | 0.10 | -48.80 | 7.14 | 6.97 | 0.21 | 6620.00% | — | 6094.00% | -4.73% | -3.09 | 1474.57% | 0.00% | 0.00% | 0.00% | -14.76 | -19.10 | — | 13.58 |
| RVTY | Revvity, Inc. | $98.31 | 11.15B | +3% | -60% | -88% | -75% | 44.87 | 1.49 | 3.79 | 20.25 | — | -6.33 | 53.08% | 12.49% | 8.46% | 3.23% | 3.28% | 1.96% | 0.48 | 3.87 | 1.68 | 1.25 | 3.92 | -1369.00% | 367.00% | -617.00% | 4.70% | 0.44 | 5.17% | 0.30% | 13.60% | 7.89% | 37.63 | 26.40 | 4.70 | 1.74 |
| SOLV | Solventum Corporation | $74.20 | 12.87B | +72% | -56% | -45% | +7% | 8.17 | 2.52 | 1.53 | 6.62 | 3.68 | -3.91 | 53.47% | 26.20% | 18.69% | 38.86% | 20.41% | 10.82% | 1.00 | 6.29 | 1.23 | 0.61 | 1.63 | 22174.00% | 86.00% | -10124.00% | -0.08% | 0.12 | -0.10% | 0.00% | 0.00% | 24.32% | 7.73 | -1686.63 | 2.03 | 2.15 |
| VTRS | Viatris Inc. | $14.93 | 17.2B | +55% | -58% | — | — | -5.23 | 1.25 | 1.29 | -79.59 | -1.12 | -2.57 | 35.06% | -18.62% | -24.58% | -21.08% | -8.56% | -8.93% | 0.98 | -5.65 | 5.06 | 2.25 | -33.11 | 46604.00% | -298.00% | -201.00% | 10.54% | 1.20 | 6.49% | 3.05% | -16.00% | 8.39% | -11.82 | 16.25 | 2.20 | 0.88 |
About Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
- CEO
- Jeffrey N. Simmons
- Employees
- 9K
- Beta
- 1.86
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($10.44 ÷ $22.51) − 1 = -53.62% (DCF, example).